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Summary The elevated levels of ras-related cellular RNA in a series of colorectal carcinomata (n = 12) was
correlated with conventional staging criteria (tumour morphology and Dukes' staging) and with clinical
outcome with particular reference to the development of metastatic disease. No direct relationship was evident
between these parameters suggesting that although abnormal expression of ras oncogenes may be critical in
the development of malignancy, variations in the level of their expression do not appear to be directly related
to clinically evident phenotypic differences.
The characterisation of transforming cellular
oncogenes in a variety of human tumours has
contributed an initial understanding of cancer and
the process of carcinogenesis at the molecular level
(for a review see Cooper, 1984), although the extent
to which abnormal expression of these genes is
directly related to variations in the clinical
behaviour of tumours is not yet clear. Elevated
levels of transcription of several oncogenes have
now been shown in a wide range of tumours
(Slamon et al., 1984; Spandidos & Agnantis, 1984;
Spandidos et al., 1985) and it has recently been
shown that amplification of an N-myc oncogene is
related to tumour stage in neuroblastoma (Brodeur
et al., 1984) whilst a study of c-myc expression in a
series of human leukaemias showed increased
expression to be apparently related to a more
immature phenotype (Birnie et al., 1986).
Activation of a ras oncogene has also been
suggested to be related, in a mouse lymphoma, to
the generation of a more aggressive tumour variant
(Vousden & Marshall, 1984).
Staging of colorectal carcinoma is currently
undertaken using Dukes' classification (Dukes &
Bussey, 1958) based on the extent of tumour
invasion and spread through bowel wall. However,
it has long been recognised that this classification
constitutes no more than a relatively crude
indication of prognostic probability (Woods, 1980),
and the clinical outcome for patients within the
different stages may vary significantly. Tumour
morphology similarly yields only a very broad
correlation with prognosis with marked inconsis-
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tencies occurring between degree of differentiation
and clinical outcome (Finlay & McArdle, 1982).
Despite initial enthusiasm regarding the potential
of carcinoembryonic antigen as a tumour marker
(see NIH Consensus Statement, 1981) it has now
been shown that the presence of elevated pre-
operative serum levels does not correlate with
clinical outcome (Lewi et al., 1984) and that
subsequent elevations are not an invariable feature
of advanced recurrent or disseminated disease
(Finlay & McArdle, 1983). Studies of ploidy in
these tumours have shown in general an inverse
relation between increasing degrees of aneuploidy
and prognosis although this is not absolute (Wolley
et al., 1982). We have recently shown, in a study
of 'occult' metastatic disease using computerised
tomography (Finlay & McArdle, 1982), that the
presence or absence of metastatic disease at the
time of clinical presentation, long known to be
associated with a dire prognosis (Bengtsson et al.,
1981), is in fact the most critical prognostic factor,
regardless of Dukes' staging and accounts almost
entirely for the anticipated pattern of mortality.
Studies of the rate of growth of these metastases
show that they in fact had been present for a mean
period of 3 years prior to surgery. This raises the
possibility that these tumours may behave consis-
tently from an early stage as metastasising or non-
metastasising variants (Finlay et al., 1982). However
the phenotypic determinants or, possibly, features
of a host response which might be responsible
for such variation remain poorly understood and
there is in particular no means of predicting the
metastatic potential of a tumour, clearly of impor-
tance in determining further therapeutic strategies.
Since we have previously reported a variable
elevation of expression of ras family oncogenes in a
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series of premalignant and malignant tumours of
the colorectum as compared to normal colonic
mucosa (Spandidos & Kerr, 1984), it was obviously
of interest to determine whether the variation in
expression we observed was related in any way to
conventional staging criteria and whether, in
particular, this could be used to predict the clinical
behaviour of these tumours.
Materials and methods
Random blocks from a series of tumours and
corresponding colonic mucosa were dissected out
from operative specimens and snap frozen in liquid
nitrogen. Our procedure for extraction of RNA for
spot hybridisation assays has already been
described in detail. (Spandidos & Kerr, 1984).
Briefly 10pg aliquots of total cellular RNA were
hybridised sequentially on nitrocellulose paper with
32P-labelled nick-translated HiHi3 (Ellis et al.,
1980) and BS9 (Ellis et al., 1981) recombinant
probes containing the viral Kirsten ras and viral
Harvey ras DNA sequences and, subsequently, as
controls to check the quantity of RNA present,
with the pL335 (Dalla Favera et al., 1982), pAM91
(Minty et al., 1982) and pHR28 probes containing
the human cellular sis, mouse actin and human 28S
ribosomal DNA sequences respectively. Similarly,
the quality of our RNA preparations were checked
by formaldehyde-agarose gel electrophoresis,
followed by ethidium bromide staining, blotting
onto nitrocellulose and hybridisation to DNA
probes.
Quantitation of the spot hybridisation reactions
following autoradiographic exposure was performed
by densitometric scanning as previously described
(Spandidos et al., 1981) and our figures were based
on an arbitrary value obtained when the ras probes
were hybridised with normal mucosa.
Histopathological reports were based on standard
6pm paraffin embedded sections stained with
haematoxylin and eosin.
Patients in the study were followed up as out-
patients at 3 monthly intervals with biannual
ultrasonography and further radiological
investigations as indicated.
Results
It is evident from Figures 1 and 2 that the degree
of elevated expression of Kirsten or Harvey ras
related sequences in our series does not appear to
correlate with either tumour morphology or Dukes'
staging since the range of values obtained, ranging
from .-2 to 20 fold for the Kirsten to 1.5 to 14
Table I Relation of Ki and Ha-ras related oncogene
expression to age, sex and clinical outcome.
Follow-up
Patient Age Sex in months Status Ki-ras Ha-ras
1 52 M 27 ND 6.3 4.5
2 83 F (9) ND" 3.5 14
3 62 F (19) DD" 19.0 9.0
4 61 F 33 LD 7.0 7.6
5 60 M (5) DDa 3.5 1.5
6 54 F (6) DD" 6.5 1.5
7 81 F (4) DDa 7.0 1.5
8 72 M 24 ND 9.0 1.5
9 75 M 36 ND 5.0 1.5
10 78 F (-) NDa,c 4.4 1.5
(post op.)
11 79 M (-) a,b 6.5 11
(post op.)
12 51 F (8) DDa 1.9 14
Status of patients at follow-up or death was assessed
and abbreviated as follows: ND-no evidence of disease;
DD-disseminated disease; LD-local disease; adead; bnot
known; Cpost-mortem assessment.
fold for the Harvey-related sequences, clearly
overlaps all histological grades and Dukes' stages.
Although follow-up is in some cases relatively
short it is, however, known that of those who will
ultimately develop disseminated disease the
majority would be expected to do so within a
period of two years (Finlay et al., 1982c). The
information in Table I thus shows that the level of
expression of these sequences does not appear to be
related to clinical outcome in general nor to the
development in particular ofmetastatic disease.
Discussion
Our results therefore indicate that, although some
elevation of Kirsten and Harvey-related ras
oncogene expression is seen in all these tumours,
variation in the amounts of RNA homologous to
the ras probes is not related to clinically apparent
phenotypic variation nor clinical outcome. If the
hypothesis relating to a heterogeneity of cells with
metastatic potential in a primary tumour (Hart &
Fidler, 1981), currently held by several authors to
be extremely contentious (Weiss et al., 1983;
Alexander, 1983), were indeed true in this tumour
type, then random sampling could obviously not be
expected to identify such variation. We have,
however, already presented evidence showing that
these tumours appear to behave consistently as
metastasising or non-metastasising variants (Finlay
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Figure 1 Relation of (a) Ki-ras and (b) Ha-ras related oncogene expression to Dukes' stage (i) and degree of
tumour differentiation (ii). In one case histology was not available.
pattern of p21 expression has been reported in
formalin-fixed paraffin-embedded sections of these
tumours by immunocytochemical techniques (Thor
et al., 1984), we (Kerr et al., 1985) and others
(Williams et al., 1985) have demonstrated, using the
monoclonal antibody Y13-259 (Furth et al., 1982)
on frozen sections of these tumours, widespread
positive staining of tumour cells with little reactivity
ofunderlying stroma. It is unfortunately not possible
to quantitate expression using such techniques. Thus,
although some variation within individual cells
cannot be excluded, it is clear from the evidence
based on presently available methods of study that
neither the presence of ras oncogene expression nor
observable differences in its level can be used to
predict variations in clinical behaviour in these
tumours.
These findings are consistent with a recently
published study which showed similar elevations of
p21 protein levels in these tumours but which was
also unable to correlate these absolutely with
conventional staging criteria, although, interestingly,
it was shown that metastatic tumour contained
relatively low levels of p21 (Gallick et al., 1985).
Although activity of a number of cellular proto-
oncogenes has been demonstrated in a variety of
tissue types and at various developmental stages
(Westin et al., 1982a, b; Muller et al., 1982, 1983), it
is not yet clear in the majority of cases what their
exact physiological roles might be. It is widely
hypothesised, however, that they may be
concerned with cell growth control and regulation
(Heldin & Westermark, 1984). Nor is it precisely
understood what part they play in the process of
carcinogenesis although they have been identified in
several cases as the active transforming genes in
3T3 transfection assays, including an activated Ki-
ras from a colonic carcinoma (Pulciani et al., 1982).
We have previously shown elevated expression of
ras family oncogenes in malignant and
premalignant tumours of the colorectum and
elevated expression as well as transforming activity
of a Ha-ras oncogene has been shown in
experimentally induced mouse skin carcinomata
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and in premalignant papillomata (Balmain et al.,
1984). It is also of interest in this context that
during experimental in vitro transformation of early
passage rodent cells, transfection with either an
activated, mutated Ha-ras oncogene or with a
normal Ha-ras proto-oncogene linked to an
enhancer induces immortalisation alone, and that
only when linked to transcriptional enhancers can a
mutated form of the gene induce complete
malignant transformation (Spandidos & Wilkie,
1984). Such results would be consistent with a role
for both quantitative and qualitative changes in ras
gene expression within an overall multi-step process
ofcarcinogenesis.
If indeed, as we have previously hypothesised,
activation of these genes at a premalignant stage
may be critical in the process of carcinogenesis but
not in itself sufficient, it may be that subsequent
event(s) whose nature is not yet clear, perhaps
involving activation of a variety of other gene loci
and possibly associated with some form of genomic
instability, are more directly involved in the
expression of a frankly malignant phenotype and its
variants. It is, however, possible that variation in
the nature of the mutation previously shown to be
associated with ras activation (Reddy et al., 1982;
Shimizu et al., 1983; Santos et al., 1984) may also
be significant in this context, although in a series of
urothelial tumours recently reported (Fujita et al.,
1984) neither the presence of a transforming ras
oncogene in DNA in a small percentage of cases
nor the presence or absence of a documented
mutation in these, appeared to be related to tumour
stage. Nonetheless, study of such variation and of
abnormal expression of cellular oncogenes, already
shown in the context of neuroblastoma even in
gross tumour specimens to be clinically significant,
as well as of other event(s) involved in the
generation of malignancy will clearly be important
in attempting to define the behaviour of these
tumours more fully.
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